| Digg It |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Management > New UK Laws on Staff Dispute Resolution and Disciplinary Procedures |
|
Digg It - New UK Laws on Staff Dispute Resolution and Disciplinary Procedures
October 2004 saw the introduction of the Employment Act 2002, which has brought a new approach to staff dispute resolution. It has long been acknowledged that disputes in the workplace are dis According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product ruptive, stressful, and costly – both for employers and employees. Once time and legal expenses are taken into account, the average cost of an employment tribunal for a UK employer is ?2, ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in 000. In addition, it is said that 50% of employees who take a case to a tribunal end up in lower paid or lower status jobs after the hearing, and almost a quarter find themselves unemployed. I lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. a recent twelve month period, the UK employment tribunal service received over 94,000 claims. But research showed that in more than 33% of cases, the employee and his or her manager had not ha here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe d any prior discussion about the problem. The new legislation in the Employment Act aims to address these problems by:
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro Since October 2004, all employers and employees hav ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc e been required to follow a new three-step process when dealing with most dismissals, disciplinary actions or grievances. If they don’t, they could face a financial penalty should a dispu easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi te reach
a tribunal. The stages in this new three-step process are as follows: nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically ut the reasons for this in writing to the employee. Similarly, if the employee has a grievance against his employer, he must put it in writing in a letter to his employer. and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ eeting to discuss the issue A face to face meeting must take place between the employer and the employee to discuss the issues raised in the letter. There must be a suitable amount of tim ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi prior to the meeting for the recipient of the letter to consider the other party’s complaint. Following the meeting, the employee must be informed of the employer’s decision and no ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a tified of their right to appeal. dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod tcome of the appeal.
The above standards are intended to be a minimum which must be met by all UK employers. However, so long as these minimum standards are complied with, companie cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin are free to personalise the procedures to suit the needs of their own business. Remember, if a dispute reaches tribunal and one of the parties has not followed the three-step process in full, tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen they will almost certainly face penalties. If an employer fails to follow the new rules, then any award made to the employee by a tribunal will be increased by a minimum of 10% up to a maxim t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel m of 50% If the employee fails to follow the procedure, any award they are adjudged to receive is reduced by a minimum of 10% up to a maximum of 50%. In light of the new regulations, all busi ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust nesses need to: y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products es of their new rights and where they can go to obtain more information
. As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de hree-step process when dealing with any disciplinary matters of staff grievances. ------ Copyright 2004 David Miles. You are welcome to reproduce this article on your website, so lo elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip ng as it is published "as is" (unedited) and with the author's bio paragraph (resource box) and copyright information included. In addition, all links to external websites must be left in place tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Dress to Impress in Your Professional Best How To Make Money From Moving House (Without Actually Moving Anywhere) Conflict Resolution - Not As Simple As A, B, or C
|